Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 7/20 | 0.94 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.94 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.94 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.94 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.94 |
| ▸ | SRC | P12931 | 2/20 | 0.94 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.94 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.94 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.94 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.88 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.88 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.88 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.88 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.88 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.83 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.83 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.83 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.83 |
| ▸ | LDHA | P00338 | 1/20 | 0.83 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9171542 | 1.00 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| SCHEMBL376008 | 1.00 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL8979 | 1.00 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL12789528 | 1.00 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL6242713 | 1.00 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL18784961 | 1.00 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL13722152 | 1.00 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL13722139 | 1.00 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL2227081 | 1.00 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL20550531 | 1.00 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2395966-B1 | COSMETIC COMPOSITION FOR SKIN CARE | LENGHEIM HUBERT (AT) | 2016-07-06 | — | — | EP | claimed |
| WO-2010091827-A2 | COSMETIC FORMULATION FOR SKIN CARE | LENGHEIM HUBERT (AT) | 2010-08-19 | — | — | WO | claimed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20250381110-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | PROCTER & GAMBLE (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250268840-A1 | USE OF NANO-CARRIERS FOR DELIVERY OF ACTIVE AGENTS | LANDA LABS (2012) LTD. (IL) | 2025-08-28 | — | — | US | disclosed |
| US-20240240170-A1 | POLYANIONIC ACIDS TO IMPROVE RECOVERY AND MINIMIZE SYSTEM LOSS | WATERS TECHNOLOGIES CORPORATION (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240209408-A1 | ENGINEERED 3-O-KINASE VARIANTS AND METHODS OF USE | CODEXIS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2024129232-A1 | ENGINEERED 3'O-KINASE VARIANTS AND METHODS OF USE | CODEXIS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| CN-118165500-A | High-strength polyurethane pultrusion frame for photovoltaic and preparation method thereof | 河北聚久复合材料有限公司 | 2024-06-11 | — | — | CN | disclosed |
| US-11965198-B2 | Method for producing target substance by bacterial fermentation | AJINOMOTO CO., INC. (JP) | 2024-04-23 | — | — | US | disclosed |
| US-20240082118-A1 | TOPICAL COMPOSITIONS AND METHODS OF PREPARING THE SAME | LANDA LABS (2012) LTD. (IL) | 2024-03-14 | — | — | US | disclosed |
| WO-2010091827-A2 | COSMETIC FORMULATION FOR SKIN CARE | LENGHEIM HUBERT (AT) | 2010-08-19 | — | — | WO | disclosed |
| US-20090317803-A1 | ENZYMATIC TIME-RESOLVED LUMINESCENT ASSAY FOR NUCLEIC ACIDS QUANTITATION | GOLOVLEV VALERI | 2009-12-24 | — | — | US | disclosed |
| WO-2009104027-A1 | THERAPEUTIC APPLICATION OF TRICICLIC AROMATIC AND SATURATED BENZO(4,5)THIENO-(2,3-D)PYRIMIDINE DERIVATES, AS WELL AS THEIR THERAPEUTICALLY ACCEPTABLE SALTS | VICHEM CHEMIE KUTATÓ KFT (HU) | 2009-08-27 | — | — | WO | disclosed |
| US-7569558-B2 | Topical delivery of trace metals for skin care | BIODERM RESEARCH (US) | 2009-08-04 | — | — | US | disclosed |
| US-20080233588-A1 | Analytical Method and Kit | ENIGMA DIAGNOSTICS LIMITED (GB) | 2008-09-25 | — | — | US | disclosed |
| US-20080233588-A1 | Analytical Method and Kit | ENIGMA DIAGNOSTICS LIMITED (GB) | 2008-09-25 | — | — | US | disclosed |
| US-20070203091-A1 | Methods and therapeutic compositions for improving liver, blood flow and skeletal muscle functions in advanced diseases and aging | RAPAPORT ELIEZER | 2007-08-30 | — | — | US | disclosed |
| US-20070203091-A1 | Methods and therapeutic compositions for improving liver, blood flow and skeletal muscle functions in advanced diseases and aging | RAPAPORT ELIEZER | 2007-08-30 | — | — | US | disclosed |
| WO-2007020384-A1 | ANALYTICAL METHOD AND KIT | ENIGMA DIAGNOSTICS LIMITED (GB) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203091-A1 | Methods and therapeutic compositions for improving liver, blood flow and skeletal muscle functions in advanced diseases and aging | PYGM, TNNC1, PYGL | P2RY1 113/4885P2RX1 420/4885P2RX3 408/4885 |
| US-20080233588-A1 | Analytical Method and Kit | RNGTT, ADAR, RNASE1 | P2RY1 371/4885P2RX1 543/4885P2RX3 496/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | P2RY1 2259/4885P2RX1 1838/4885P2RX3 1239/4885 |
| US-20250381110-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | SQSTM1, BECN1, CUTA | P2RY1 1077/4885P2RX1 1236/4885P2RX3 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.